{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:39:10Z","timestamp":1794494350073,"version":"4.9.1"},"reference-count":272,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41581-025-01006-4","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:00:57Z","timestamp":1758625257000},"page":"50-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A guide to uraemic toxicity"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7641-4707","authenticated-orcid":false,"given":"Griet","family":"Glorieux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-7884","authenticated-orcid":false,"given":"St\u00e9phane","family":"Burtey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-4321","authenticated-orcid":false,"given":"Pieter","family":"Evenepoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-2967","authenticated-orcid":false,"given":"Joachim","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-2420","authenticated-orcid":false,"given":"Laetitia","family":"Koppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-1074","authenticated-orcid":false,"given":"Rosalinde","family":"Masereeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2633-1636","authenticated-orcid":false,"given":"Raymond","family":"Vanholder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"1006_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrneph.2017.52","volume":"13","author":"C Zoccali","year":"2017","unstructured":"Zoccali, C. et al. The systemic nature of CKD. Nat. Rev. Nephrol. 13, 344\u2013358 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian, M. et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24, 302\u2013308 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR3","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1681\/ASN.2018101037","volume":"30","author":"EYF Wan","year":"2019","unstructured":"Wan, E. Y. F. et al. Burden of CKD and cardiovascular disease on life expectancy and health service utilization: a cohort study of Hong Kong Chinese hypertensive patients. J. Am. Soc. Nephrol. 30, 1991\u20131999 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41581-021-00518-z","volume":"18","author":"K Kalantar-Zadeh","year":"2022","unstructured":"Kalantar-Zadeh, K. et al. Patient-centred approaches for the management of unpleasant symptoms in kidney disease. Nat. Rev. Nephrol. 18, 185\u2013198 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR5","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","volume":"32","author":"RN Foley","year":"1998","unstructured":"Foley, R. N., Parfrey, P. S. & Sarnak, M. J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32, S112\u2013S119 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"1006_CR6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","volume":"18","author":"K Matsushita","year":"2022","unstructured":"Matsushita, K. et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat. Rev. Nephrol. 18, 696\u2013707 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jamacardio.2019.0375","volume":"4","author":"ZJ Modi","year":"2019","unstructured":"Modi, Z. J. et al. Risk of cardiovascular disease and mortality in young adults with end-stage renal disease: an analysis of the US renal data system. JAMA Cardiol. 4, 353\u2013362 (2019).","journal-title":"JAMA Cardiol."},{"key":"1006_CR8","unstructured":"NCD_Alliance. Home \/ WHY NCDs \/ NCDs \/ Chronic Kidney Disease. ncdalliance.org https:\/\/ncdalliance.org\/why-ncds\/ncds\/chronic-kidney-disease (2017)."},{"key":"1006_CR9","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.2215\/CJN.02660221","volume":"16","author":"MH Rosner","year":"2021","unstructured":"Rosner, M. H. et al. Classification of uremic toxins and their role in kidney failure. Clin. J. Am. Soc. Nephrol. 16, 1918\u20131928 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1006_CR10","first-page":"396","volume":"18","author":"Jaksch","year":"1861","unstructured":"Jaksch On ur\u00e6mia. Chic. Med. J. 18, 396\u2013397 (1861).","journal-title":"Chic. Med. J."},{"key":"1006_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archinte.1970.00310110113019","volume":"126","author":"PL Balestri","year":"1970","unstructured":"Balestri, P. L., Biagini, M., Rindi, P. & Giovannetti, S. Uremic toxins. Arch. Intern. Med. 126, 843\u2013845 (1970).","journal-title":"Arch. Intern. Med."},{"key":"1006_CR12","first-page":"1127","volume":"12","author":"I Desi","year":"1957","unstructured":"Desi, I., Feher, E., Szold, A., Weisz, P. & Kadas, T. [Determination of toxicity of uremic blood treated with ion exchange resins]. Z. Gesamte Inn. Med. 12, 1127\u20131130 (1957).","journal-title":"Z. Gesamte Inn. Med."},{"key":"1006_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0272-6386(81)80011-X","volume":"1","author":"AL Babb","year":"1981","unstructured":"Babb, A. L., Ahmad, S., Bergstr\u00f6m, J. & Scribner, B. H. The middle molecule hypothesis in perspective. Am. J. Kidney Dis. 1, 46\u201350 (1981).","journal-title":"Am. J. Kidney Dis."},{"key":"1006_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000328961","volume":"173","author":"M Thomas","year":"2011","unstructured":"Thomas, M., Moriyama, K. & Ledebo, I. AN69: evolution of the world\u2019s first high permeability membrane. Contrib. Nephrol. 173, 119\u2013129 (2011).","journal-title":"Contrib. Nephrol."},{"key":"1006_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0006-291X(85)91948-5","volume":"129","author":"F Gejyo","year":"1985","unstructured":"Gejyo, F. et al. A new form of amyloid protein associated with chronic hemodialysis was identified as \u03b22-microglobulin. Biochem. Biophys. Res. Commun. 129, 701\u2013706 (1985).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1006_CR16","first-page":"1","volume":"46","author":"A Kasanen","year":"1957","unstructured":"Kasanen, A. Serum indican and endogenous indican clearance in renal insufficiency. Ann. Med. Intern. Fenn. Suppl. 46, 1\u201371 (1957).","journal-title":"Ann. Med. Intern. Fenn. Suppl."},{"key":"1006_CR17","first-page":"96","volume":"124","author":"T Niwa","year":"1994","unstructured":"Niwa, T. & Ise, M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J. Lab. Clin. Med. 124, 96\u2013104 (1994).","journal-title":"J. Lab. Clin. Med."},{"key":"1006_CR18","doi-asserted-by":"crossref","unstructured":"Vanholder, R., Glorieux, G., De Smet, R. & Lameire, N. New insights in uremic toxins. Kidney Int. Suppl. 63, S6\u2013S10.","DOI":"10.1046\/j.1523-1755.63.s84.43.x"},{"key":"1006_CR19","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","volume":"63","author":"R Vanholder","year":"2003","unstructured":"Vanholder, R. et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63, 1934\u20131943 (2003).","journal-title":"Kidney Int."},{"key":"1006_CR20","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1681\/ASN.2011121175","volume":"23","author":"F Duranton","year":"2012","unstructured":"Duranton, F. et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 23, 1258\u20131270 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrneph.2017.30","volume":"13","author":"B Hocher","year":"2017","unstructured":"Hocher, B. & Adamski, J. Metabolomics for clinical use and research in chronic kidney disease. Nat. Rev. Nephrol. 13, 269\u2013284 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100955","volume":"7","author":"R Vanholder","year":"2025","unstructured":"Vanholder, R. et al. Metabolomics to identify unclassified uremic toxins: a comprehensive literature review. Kidney Med. 7, 100955 (2025).","journal-title":"Kidney Med."},{"key":"1006_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2215\/CJN.10010818","volume":"14","author":"S Luo","year":"2019","unstructured":"Luo, S. et al. Serum metabolomic alterations associated with proteinuria in CKD. Clin. J. Am. Soc. Nephrol. 14, 342\u2013353 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1006_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213764","volume":"14","author":"SM Titan","year":"2019","unstructured":"Titan, S. M. et al. Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: results from the Progredir cohort. PLoS ONE 14, e0213764 (2019).","journal-title":"PLoS ONE"},{"key":"1006_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","volume":"472","author":"Z Wang","year":"2011","unstructured":"Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57\u201363 (2011).","journal-title":"Nature"},{"key":"1006_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161696","volume":"7","author":"D Wen","year":"2022","unstructured":"Wen, D. et al. Metabolite profiling of CKD progression in the chronic renal insufficiency cohort study. JCI insight 7, e161696 (2022).","journal-title":"JCI insight"},{"key":"1006_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2215\/CJN.0000000000000318","volume":"19","author":"AM Lee","year":"2024","unstructured":"Lee, A. M. et al. Circulating metabolomic associations with neurocognitive outcomes in pediatric CKD. Clin. J. Am. Soc. Nephrol. 19, 13\u201325 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1006_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09735-4","volume":"10","author":"K Kikuchi","year":"2019","unstructured":"Kikuchi, K. et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat. Commun. 10, 1835 (2019).","journal-title":"Nat. Commun."},{"key":"1006_CR29","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/ndt\/gfv048","volume":"30","author":"PR Gajjala","year":"2015","unstructured":"Gajjala, P. R., Fliser, D., Speer, T., Jankowski, V. & Jankowski, J. Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrol. Dial. Transplant. 30, 1814\u20131824 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41581-024-00837-x","volume":"20","author":"H Noels","year":"2024","unstructured":"Noels, H. et al. Post-translational modifications in kidney diseases and associated cardiovascular risk. Nat. Rev. Nephrol. 20, 495\u2013512 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semnephrol.2014.02.012","volume":"34","author":"B Meijers","year":"2014","unstructured":"Meijers, B., Glorieux, G., Poesen, R. & Bakker, S. J. Nonextracorporeal methods for decreasing uremic solute concentration: a future way to go? Semin. Nephrol. 34, 228\u2013243 (2014).","journal-title":"Semin. Nephrol."},{"key":"1006_CR32","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.kint.2017.02.011","volume":"92","author":"E Mishima","year":"2017","unstructured":"Mishima, E. et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 92, 634\u2013645 (2017).","journal-title":"Kidney Int."},{"issue":"Supp. 114","key":"1006_CR33","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1038\/ki.2009.402","volume":"76","author":"P Evenepoel","year":"2009","unstructured":"Evenepoel, P, Meijers, B. K., Bammens, B. R. & Verbeke, K. Uremic toxins originating from colonic microbial metabolism. Kidney Int. 76 (Supp. 114), S12\u2013S19 (2009).","journal-title":"Kidney Int."},{"key":"1006_CR34","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1021\/pr200093w","volume":"10","author":"WR Wikoff","year":"2011","unstructured":"Wikoff, W. R., Nagle, M. A., Kouznetsova, V. L., Tsigelny, I. F. & Nigam, S. K. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J. Proteome Res. 10, 2842\u20132851 (2011).","journal-title":"J. Proteome Res."},{"key":"1006_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3390\/toxins14030221","volume":"14","author":"R Vanholder","year":"2022","unstructured":"Vanholder, R., Nigam, S. K., Burtey, S. & Glorieux, G. What if not all metabolites from the uremic toxin generating pathways are toxic? A hypothesis. Toxins 14, 221 (2022).","journal-title":"Toxins"},{"key":"1006_CR36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1124\/mol.109.056564","volume":"76","author":"SY Ahn","year":"2009","unstructured":"Ahn, S. Y. & Nigam, S. K. Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis. Mol. Pharmacol. 76, 481\u2013490 (2009).","journal-title":"Mol. Pharmacol."},{"key":"1006_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41581-019-0111-1","volume":"15","author":"SK Nigam","year":"2019","unstructured":"Nigam, S. K. & Bush, K. T. Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling. Nat. Rev. Nephrol. 15, 301\u2013316 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1681\/ASN.2014010021","volume":"26","author":"CY Sun","year":"2015","unstructured":"Sun, C. Y. et al. Protein-bound uremic toxins induce tissue remodeling by targeting the EGF receptor. J. Am. Soc. Nephrol. 26, 281\u2013290 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00467-015-3181-8","volume":"31","author":"BD Shepard","year":"2016","unstructured":"Shepard, B. D. & Pluznick, J. L. How does your kidney smell? Emerging roles for olfactory receptors in renal function. Pediatr. Nephrol. 31, 715\u2013723 (2016).","journal-title":"Pediatr. Nephrol."},{"key":"1006_CR40","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1124\/dmd.115.065250","volume":"43","author":"W Wu","year":"2015","unstructured":"Wu, W. et al. Shared ligands between organic anion transporters (OAT1 and OAT6) and odorant receptors. Drug Metab. Dispos. 43, 1855\u20131863 (2015).","journal-title":"Drug Metab. Dispos."},{"key":"1006_CR41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/toxins12060391","volume":"12","author":"SM Mihaila","year":"2020","unstructured":"Mihaila, S. M. et al. Drugs commonly applied to kidney patients may compromise renal tubular uremic toxins excretion. Toxins 12, 391 (2020).","journal-title":"Toxins"},{"key":"1006_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018438","volume":"6","author":"HA Mutsaers","year":"2011","unstructured":"Mutsaers, H. A. et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS ONE 6, e18438 (2011).","journal-title":"PLoS ONE"},{"key":"1006_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd4461","volume":"14","author":"SK Nigam","year":"2015","unstructured":"Nigam, S. K. What do drug transporters really do? Nat. Rev. Drug. Discov. 14, 29\u201344 (2015).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1006_CR44","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.bcp.2009.01.010","volume":"77","author":"N Kimura","year":"2009","unstructured":"Kimura, N., Masuda, S., Katsura, T. & Inui, K. Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochem. Pharmacol. 77, 1429\u20131436 (2009).","journal-title":"Biochem. Pharmacol."},{"key":"1006_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039641","volume":"7","author":"KL Kuo","year":"2012","unstructured":"Kuo, K. L., Zhu, H., McNamara, P. J. & Leggas, M. Localization and functional characterization of the rat Oatp4c1 transporter in an in vitro cell system and rat tissues. PLoS ONE 7, e39641 (2012).","journal-title":"PLoS ONE"},{"key":"1006_CR46","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00424-013-1307-z","volume":"465","author":"CM Schophuizen","year":"2013","unstructured":"Schophuizen, C. M. et al. Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the organic cation transporter. Pflugers Arch. 465, 1701\u20131714 (2013).","journal-title":"Pflugers Arch."},{"key":"1006_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213747","volume":"14","author":"E Taghikhani","year":"2019","unstructured":"Taghikhani, E., Maas, R., Fromm, M. F. & K\u00f6nig, J. The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine. PLoS ONE 14, e0213747 (2019).","journal-title":"PLoS ONE"},{"key":"1006_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165741","volume":"1866","author":"N Pengrattanachot","year":"2020","unstructured":"Pengrattanachot, N. et al. Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165741 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1006_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107647","volume":"217","author":"J Zhang","year":"2021","unstructured":"Zhang, J., Wang, H., Fan, Y., Yu, Z. & You, G. Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination. Pharmacol. Ther. 217, 107647 (2021).","journal-title":"Pharmacol. Ther."},{"key":"1006_CR50","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1681\/ASN.2017030361","volume":"29","author":"T Santana Machado","year":"2018","unstructured":"Santana Machado, T. et al. Indoxyl sulfate upregulates liver P-glycoprotein expression and activity through aryl hydrocarbon receptor signaling. J. Am. Soc. Nephrol. 29, 906\u2013918 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR51","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/ckj\/sfw010","volume":"9","author":"V Bhatnagar","year":"2016","unstructured":"Bhatnagar, V. et al. Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling. Clin. Kidney J. 9, 444\u2013453 (2016).","journal-title":"Clin. Kidney J."},{"key":"1006_CR52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172341","volume":"8","author":"VS Ermakov","year":"2023","unstructured":"Ermakov, V. S., Granados, J. C. & Nigam, S. K. Remote effects of kidney drug transporter OAT1 on gut microbiome composition and urate homeostasis. JCI insight 8, e172341 (2023).","journal-title":"JCI insight"},{"key":"1006_CR53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/bdd.2149","volume":"39","author":"K Morimoto","year":"2018","unstructured":"Morimoto, K. et al. Intestinal secretion of indoxyl sulfate as a possible compensatory excretion pathway in chronic kidney disease. Biopharm. Drug Dispos. 39, 328\u2013334 (2018).","journal-title":"Biopharm. Drug Dispos."},{"key":"1006_CR54","doi-asserted-by":"publisher","first-page":"16105","DOI":"10.1073\/pnas.1821809116","volume":"116","author":"J Jansen","year":"2019","unstructured":"Jansen, J. et al. Remote sensing and signaling in kidney proximal tubules stimulates gut microbiome-derived organic anion secretion. Proc. Natl Acad. Sci. USA 116, 16105\u201316110 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1006_CR55","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.3390\/ijms21072483","volume":"21","author":"C Makhloufi","year":"2020","unstructured":"Makhloufi, C. et al. Female AhR knockout mice develop a minor renal insufficiency in an adenine-diet model of chronic kidney disease. Int. J. Mol. Sci. 21, 2483 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1006_CR56","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.3390\/pharmaceutics14112307","volume":"14","author":"X Gou","year":"2022","unstructured":"Gou, X., Ran, F., Yang, J., Ma, Y. & Wu, X. Construction and evaluation of a novel organic anion transporter 1\/3 CRISPR\/Cas9 double-knockout rat model. Pharmaceutics 14, 2307 (2022).","journal-title":"Pharmaceutics"},{"key":"1006_CR57","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/ndt\/gfae220","volume":"40","author":"M Lauriola","year":"2025","unstructured":"Lauriola, M. et al. Dietary protein intake and the tubular handling of indoxyl sulfate. Nephrol. Dial. Transplant. 40, 739\u2013750 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/toxins9040114","volume":"9","author":"E Castillo-Rodr\u00edguez","year":"2017","unstructured":"Castillo-Rodr\u00edguez, E. et al. Inflammatory cytokines as uremic toxins: \u201cNi Son Todos Los Que Estan, Ni Estan Todos Los Que Son\u201d. Toxins 9, 114 (2017).","journal-title":"Toxins"},{"key":"1006_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/toxins9020052","volume":"9","author":"T Gryp","year":"2017","unstructured":"Gryp, T., Vanholder, R., Vaneechoutte, M. & Glorieux, G. p-Cresyl sulfate. Toxins 9, 52 (2017).","journal-title":"Toxins"},{"key":"1006_CR60","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/toxins8120369","volume":"8","author":"P Kuczera","year":"2016","unstructured":"Kuczera, P., Adamczak, M. & Wiecek, A. Fibroblast growth factor-23-a potential uremic toxin. Toxins 8, 369 (2016).","journal-title":"Toxins"},{"key":"1006_CR61","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/toxins8120358","volume":"8","author":"SC Leong","year":"2016","unstructured":"Leong, S. C. & Sirich, T. L. Indoxyl sulfate-review of toxicity and therapeutic strategies. Toxins 8, 358 (2016).","journal-title":"Toxins"},{"key":"1006_CR62","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ndt\/gfx039","volume":"33","author":"R Vanholder","year":"2018","unstructured":"Vanholder, R., Gryp, T. & Glorieux, G. Urea and chronic kidney disease: the comeback of the century? (in uraemia research). Nephrol. Dial. Transplant. 33, 4\u201312 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/toxins10010033","volume":"10","author":"R Vanholder","year":"2018","unstructured":"Vanholder, R., Pletinck, A., Schepers, E. & Glorieux, G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins 10, 33 (2018).","journal-title":"Toxins"},{"key":"1006_CR64","first-page":"10972","volume":"15","author":"H Matsuki","year":"2023","unstructured":"Matsuki, H. et al. Chronic kidney disease causes blood-brain barrier breakdown via urea-activated matrix metalloproteinase-2 and insolubility of tau protein. Aging 15, 10972\u201310995 (2023).","journal-title":"Aging"},{"key":"1006_CR65","doi-asserted-by":"publisher","first-page":"175905","DOI":"10.1016\/j.ejphar.2023.175905","volume":"957","author":"BY Huang","year":"2023","unstructured":"Huang, B. Y. et al. High urea induces anxiety disorders associated with chronic kidney disease by promoting abnormal proliferation of OPC in amygdala. Eur. J. Pharmacol. 957, 175905 (2023).","journal-title":"Eur. J. Pharmacol."},{"key":"1006_CR66","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/toxins16070326","volume":"16","author":"H Levassort","year":"2024","unstructured":"Levassort, H. et al. Urea level and depression in patients with chronic kidney disease. Toxins 16, 326 (2024).","journal-title":"Toxins"},{"key":"1006_CR67","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.kint.2017.08.033","volume":"93","author":"Y Xie","year":"2018","unstructured":"Xie, Y. et al. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney Int. 93, 741\u2013752 (2018).","journal-title":"Kidney Int."},{"key":"1006_CR68","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/ndt\/gfac045","volume":"38","author":"SM Laville","year":"2023","unstructured":"Laville, S. M. et al. Urea levels and cardiovascular disease in patients with chronic kidney disease. Nephrol. Dialysis Transplant. 38, 184\u2013192 (2023).","journal-title":"Nephrol. Dialysis Transplant."},{"key":"1006_CR69","doi-asserted-by":"publisher","first-page":"8296","DOI":"10.1096\/fj.202000214RR","volume":"34","author":"A Kuma","year":"2020","unstructured":"Kuma, A. et al. Inhibition of urea transporter ameliorates uremic cardiomyopathy in chronic kidney disease. FASEB J. 34, 8296\u20138309 (2020).","journal-title":"FASEB J."},{"key":"1006_CR70","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1373\/clinchem.2011.163188","volume":"57","author":"S Jaisson","year":"2011","unstructured":"Jaisson, S., Pietrement, C. & Gillery, P. Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin. Chem. 57, 1499\u20131505 (2011).","journal-title":"Clin. Chem."},{"key":"1006_CR71","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/ndt\/gfad201","volume":"39","author":"SJ Wu","year":"2024","unstructured":"Wu, S. J. et al. Serum uric acid levels and health outcomes in CKD: a prospective cohort study. Nephrol. Dial. Transplant. 39, 510\u2013519 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR72","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve, S. V. et al. Effects of allopurinol on the progression of chronic kidney disease. N. Engl. J. Med. 382, 2504\u20132513 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR73","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria, A. et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N. Engl. J. Med. 382, 2493\u20132503 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR74","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1681\/ASN.0000000000000326","volume":"35","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink, H. J. L. et al. Combination treatment with verinurad and allopurinol in CKD: a randomized placebo and active controlled trial. J. Am. Soc. Nephrol. 35, 594\u2013606 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR75","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jdiacomp.2017.12.006","volume":"32","author":"CB Triches","year":"2018","unstructured":"Triches, C. B., Quinto, M., Mayer, S., Batista, M. & Zanella, M. T. Relation of asymmetrical dimethylarginine levels with renal outcomes in hypertensive patients with and without type 2 diabetes mellitus. J. Diabetes Complications 32, 316\u2013320 (2018).","journal-title":"J. Diabetes Complications"},{"key":"1006_CR76","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/jcm14041051","volume":"14","author":"S Kobayashi","year":"2025","unstructured":"Kobayashi, S. et al. Asymmetric dimethylarginine (ADMA) as a novel risk factor for progression of coronary artery calcification in patients with chronic kidney disease. J. Clin. Med. 14, 1051 (2025).","journal-title":"J. Clin. Med."},{"key":"1006_CR77","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00392-017-1172-4","volume":"107","author":"IE Emrich","year":"2018","unstructured":"Emrich, I. E. et al. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease. Clin. Res. Cardiol. 107, 201\u2013213 (2018).","journal-title":"Clin. Res. Cardiol."},{"key":"1006_CR78","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.thromres.2022.03.025","volume":"213","author":"C Eyileten","year":"2022","unstructured":"Eyileten, C. et al. High concentration of symmetric dimethylarginine is associated with low platelet reactivity and increased bleeding risk in patients with acute coronary syndrome. Thromb. Res. 213, 195\u2013202 (2022).","journal-title":"Thromb. Res."},{"key":"1006_CR79","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034994","volume":"13","author":"J Hannemann","year":"2024","unstructured":"Hannemann, J. et al. Symmetric dimethylarginine predicts previously undetected atrial fibrillation in patients with ischemic stroke. J. Am. Heart Assoc. 13, e034994 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1006_CR80","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.biochi.2021.06.020","volume":"189","author":"L Koppe","year":"2021","unstructured":"Koppe, L. et al. The protein-bound uremic toxin p-cresyl-sulfate promotes intracellular ROS production and lipid peroxidation in 3T3-L1 adipose cells. Biochimie 189, 137\u2013143 (2021).","journal-title":"Biochimie"},{"key":"1006_CR81","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10565-019-09509-0","volume":"36","author":"YS Peng","year":"2020","unstructured":"Peng, Y. S., Syu, J. P., Wang, S. D., Pan, P. C. & Kung, H. N. BSA-bounded p-cresyl sulfate potentiates the malignancy of bladder carcinoma by triggering cell migration and EMT through the ROS\/Src\/FAK signaling pathway. Cell Biol. Toxicol. 36, 287\u2013300 (2020).","journal-title":"Cell Biol. Toxicol."},{"key":"1006_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.114984","volume":"198","author":"R Stafim da Cunha","year":"2022","unstructured":"Stafim da Cunha, R. et al. Uremic toxins activate CREB\/ATF1 in endothelial cells related to chronic kidney disease. Biochem. Pharmacol. 198, 114984 (2022).","journal-title":"Biochem. Pharmacol."},{"key":"1006_CR83","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.toxlet.2022.06.006","volume":"367","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Damage of uremic myocardium by p-cresyl sulfate and the ameliorative effect of Klotho by regulating SIRT6 ubiquitination. Toxicol. Lett. 367, 19\u201331 (2022).","journal-title":"Toxicol. Lett."},{"key":"1006_CR84","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bbrc.2019.12.022","volume":"523","author":"SD Rodrigues","year":"2020","unstructured":"Rodrigues, S. D. et al. Uremic toxins promote accumulation of oxidized protein and increased sensitivity to hydrogen peroxide in endothelial cells by impairing the autophagic flux. Biochem. Biophys. Res. Commun. 523, 123\u2013129 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1006_CR85","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1681\/ASN.2018060609","volume":"30","author":"B Opdebeeck","year":"2019","unstructured":"Opdebeeck, B. et al. Indoxyl sulfate and p-cresyl sulfate promote vascular calcification and associate with glucose intolerance. J. Am. Soc. Nephrol. 30, 751\u2013766 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR86","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.taap.2018.01.025","volume":"342","author":"T Shiba","year":"2018","unstructured":"Shiba, T. et al. p-Cresyl sulfate decreases peripheral B cells in mice with adenine-induced renal dysfunction. Toxicol. Appl. Pharmacol. 342, 50\u201359 (2018).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1006_CR87","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/ndt\/gfab004","volume":"36","author":"G Glorieux","year":"2021","unstructured":"Glorieux, G. et al. Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease. Nephrol. Dial. Transplant. 36, 998\u20131005 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR88","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3390\/jpm12081239","volume":"12","author":"F Verbeke","year":"2022","unstructured":"Verbeke, F., Vanholder, R., Van Biesen, W. & Glorieux, G. Contribution of hypoalbuminemia and anemia to the prognostic value of plasma p-cresyl sulfate and p-cresyl glucuronide for cardiovascular outcome in chronic kidney disease. J. Pers. Med. 12, 1239 (2022).","journal-title":"J. Pers. Med."},{"key":"1006_CR89","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2016-10-744060","volume":"129","author":"K Yang","year":"2017","unstructured":"Yang, K. et al. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice. Blood 129, 2667\u20132679 (2017).","journal-title":"Blood"},{"key":"1006_CR90","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/ndt\/gfx252","volume":"33","author":"H Hamano","year":"2018","unstructured":"Hamano, H. et al. The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease. Nephrol. Dial. Transplant. 33, 586\u2013597 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR91","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.3390\/ijms24098031","volume":"24","author":"A Ribeiro","year":"2023","unstructured":"Ribeiro, A. et al. Uremic toxin indoxyl sulfate promotes macrophage-associated low-grade inflammation and epithelial cell senescence. Int. J. Mol. Sci. 24, 8031 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1006_CR92","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.arcmed.2019.12.020","volume":"51","author":"GGC Rodrigues","year":"2020","unstructured":"Rodrigues, G. G. C. et al. Indoxyl sulfate contributes to uremic sarcopenia by inducing apoptosis in myoblasts. Arch. Med. Res. 51, 21\u201329 (2020).","journal-title":"Arch. Med. Res."},{"key":"1006_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2023.137594","volume":"820","author":"K \u0141ukawski","year":"2024","unstructured":"\u0141ukawski, K., Raszewski, G. & Czuczwar, S. J. Effects of the uremic toxin indoxyl sulfate on seizure activity, learning and brain oxidative stress parameters in mice. Neurosci. Lett. 820, 137594 (2024).","journal-title":"Neurosci. Lett."},{"key":"1006_CR94","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1681\/ASN.2019070728","volume":"31","author":"M Bobot","year":"2020","unstructured":"Bobot, M. et al. Uremic toxic blood-brain barrier disruption mediated by AhR activation leads to cognitive impairment during experimental renal dysfunction. J. Am. Soc. Nephrol. 31, 1509\u20131521 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR95","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41581-025-00963-0","volume":"21","author":"G Capasso","year":"2025","unstructured":"Capasso, G. et al. Drivers and mechanisms of cognitive decline in chronic kidney disease. Nat. Rev. Nephrol. 21, 536\u2013552 (2025).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR96","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/toxins17010017","volume":"17","author":"Y Ichisaka","year":"2025","unstructured":"Ichisaka, Y. et al. The role of indoxyl sulfate in exacerbating colorectal cancer during chronic kidney disease progression: insights into the Akt\/\u03b2-catenin\/c-Myc and AhR\/c-Myc pathways in HCT-116 colorectal cancer cells. Toxins 17, 17 (2025).","journal-title":"Toxins"},{"key":"1006_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2022.100025","volume":"103","author":"S Saito","year":"2023","unstructured":"Saito, S., Koya, Y., Kajiyama, H., Yamashita, M. & Nawa, A. Indoxyl sulfate promotes metastatic characteristics of ovarian cancer cells via aryl hydrocarbon receptor-mediated downregulation of the Mas receptor. Lab. Invest. 103, 100025 (2023).","journal-title":"Lab. Invest."},{"key":"1006_CR98","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/gutjnl-2024-333479","volume":"74","author":"F Lou","year":"2025","unstructured":"Lou, F. et al. Dysbiotic oral microbiota-derived kynurenine, induced by chronic restraint stress, promotes head and neck squamous cell carcinoma by enhancing CD8+ T cell exhaustion. Gut 74, 935\u2013947 (2025).","journal-title":"Gut"},{"key":"1006_CR99","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2478\/v10039-010-0015-6","volume":"55","author":"K Pawlak","year":"2010","unstructured":"Pawlak, K., My\u015bliwiec, M. & Pawlak, D. Kynurenine pathway \u2014 a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv. Med. Sci. 55, 196\u2013203 (2010).","journal-title":"Adv. Med. Sci."},{"key":"1006_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118015","volume":"186","author":"S Mohiti","year":"2025","unstructured":"Mohiti, S., Alizadeh, E., Bisgaard, L. S., Ebrahimi-Mameghani, M. & Christoffersen, C. The AhR\/P38 MAPK pathway mediates kynurenine-induced cardiomyocyte damage: the dual role of resveratrol in apoptosis and autophagy. Biomed. Pharmacother. 186, 118015 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"1006_CR101","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3390\/ph17080983","volume":"17","author":"P Carrillo-Mora","year":"2024","unstructured":"Carrillo-Mora, P. et al. Kynurenines and inflammation: a remarkable axis for multiple sclerosis treatment. Pharmaceuticals 17, 983 (2024).","journal-title":"Pharmaceuticals"},{"key":"1006_CR102","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432\u20132439 (2011).","journal-title":"JAMA"},{"key":"1006_CR103","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/hdi.12190","volume":"18","author":"WL Lau","year":"2014","unstructured":"Lau, W. L., Kalantar-Zadeh, K., Kovesdy, C. P. & Mehrotra, R. Alkaline phosphatase: better than PTH as a marker of cardiovascular and bone disease? Hemodial. Int. 18, 720\u2013724 (2014).","journal-title":"Hemodial. Int."},{"key":"1006_CR104","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.kint.2025.01.024","volume":"107","author":"MAA Fuchs","year":"2025","unstructured":"Fuchs, M. A. A. et al. Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease. Kidney Int. 107, 852\u2013868 (2025).","journal-title":"Kidney Int."},{"key":"1006_CR105","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/ndt\/gfy006","volume":"33","author":"M Leifheit-Nestler","year":"2018","unstructured":"Leifheit-Nestler, M. et al. Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts. Nephrol. Dial. Transplant. 33, 1722\u20131734 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2022.100003","volume":"103","author":"T Saito","year":"2023","unstructured":"Saito, T. et al. Fibroblast growth factor 23 exacerbates cardiac fibrosis in deoxycorticosterone acetate-salt mice with hypertension. Lab. Invest. 103, 100003 (2023).","journal-title":"Lab. Invest."},{"key":"1006_CR107","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5551\/jat.63460","volume":"30","author":"LW Guo","year":"2023","unstructured":"Guo, L. W., Wang, Y. K., Li, S. J., Yin, G. T. & Li, D. Elevated fibroblast growth factor 23 impairs endothelial function through the NF-\u03baB signaling pathway. J. Atheroscler. Thromb. 30, 138\u2013149 (2023).","journal-title":"J. Atheroscler. Thromb."},{"key":"1006_CR108","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/ndt\/gfac220","volume":"38","author":"N Vergara","year":"2023","unstructured":"Vergara, N. et al. The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function. Nephrol. Dial. Transplant. 38, 322\u2013343 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03210-0","volume":"7","author":"K Yang","year":"2017","unstructured":"Yang, K. et al. Fibroblast growth factor 23 weakens chemotaxis of human blood neutrophils in microfluidic devices. Sci. Rep. 7, 3100 (2017).","journal-title":"Sci. Rep."},{"key":"1006_CR110","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fnbeh.2019.00244","volume":"13","author":"SM Chen","year":"2019","unstructured":"Chen, S. M. et al. Hydrogen sulfide attenuates \u03b22-microglobulin-induced cognitive dysfunction: involving recovery of hippocampal autophagic flux. Front. Behav. Neurosci. 13, 244 (2019).","journal-title":"Front. Behav. Neurosci."},{"key":"1006_CR111","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejphar.2017.07.007","volume":"810","author":"T Andoh","year":"2017","unstructured":"Andoh, T., Maki, T., Li, S. & Uta, D. \u03b22-microglobulin elicits itch-related responses in mice through the direct activation of primary afferent neurons expressing transient receptor potential vanilloid 1. Eur. J. Pharmacol. 810, 134\u2013140 (2017).","journal-title":"Eur. J. Pharmacol."},{"key":"1006_CR112","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2019.01.017","volume":"847","author":"S Li","year":"2019","unstructured":"Li, S., Andoh, T., Zhang, Q., Uta, D. & Kuraishi, Y. \u03b22-microglobulin, interleukin-31, and arachidonic acid metabolites (leukotriene B4 and thromboxane A2) are involved in chronic renal failure-associated itch-associated responses in mice. Eur. J. Pharmacol. 847, 19\u201325 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"1006_CR113","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeae046","volume":"4","author":"T Knopp","year":"2024","unstructured":"Knopp, T. et al. Myeloid cell-derived interleukin-6 induces vascular dysfunction and vascular and systemic inflammation. Eur. Heart J. Open 4, oeae046 (2024).","journal-title":"Eur. Heart J. Open"},{"key":"1006_CR114","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187711","volume":"135","author":"JA Keefe","year":"2025","unstructured":"Keefe, J. A. et al. Macrophage-mediated interleukin-6 signaling drives ryanodine receptor-2 calcium leak in postoperative atrial fibrillation. J. Clin. Invest. 135, e187711 (2025).","journal-title":"J. Clin. Invest."},{"key":"1006_CR115","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1681\/ASN.2020050595","volume":"32","author":"PE Pergola","year":"2021","unstructured":"Pergola, P. E. et al. Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1\/2 multicenter, randomized, double-blind, placebo-controlled trial. J. Am. Soc. Nephrol. 32, 211\u2013222 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR116","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.kint.2018.02.026","volume":"94","author":"K Durlacher-Betzer","year":"2018","unstructured":"Durlacher-Betzer, K. et al. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int. 94, 315\u2013325 (2018).","journal-title":"Kidney Int."},{"key":"1006_CR117","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbi.2025.02.009","volume":"126","author":"FJ Velloso","year":"2025","unstructured":"Velloso, F. J., Zaritsky, R., Houbeika, R. Y., Rios, N. & Levison, S. W. Interleukin-6 produces behavioral deficits in pre-pubescent mice independent of neuroinflammation. Brain, Behav. Immun. 126, 275\u2013288 (2025).","journal-title":"Brain, Behav. Immun."},{"key":"1006_CR118","doi-asserted-by":"publisher","first-page":"12036","DOI":"10.1096\/fj.201900016RR","volume":"33","author":"S Keshari","year":"2019","unstructured":"Keshari, S. et al. IL-6\/p-BTK\/p-ERK signaling mediates calcium phosphate-induced pruritus. FASEB J. 33, 12036\u201312046 (2019).","journal-title":"FASEB J."},{"key":"1006_CR119","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJMra071313","volume":"357","author":"TW Meyer","year":"2007","unstructured":"Meyer, T. W. & Hostetter, T. H. Uremia. N. Engl. J. Med. 357, 1316\u20131325 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR120","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/toxins10060218","volume":"10","author":"L H\u00e9naut","year":"2018","unstructured":"H\u00e9naut, L., Mary, A., Chillon, J. M., Kamel, S. & Massy, Z. A. The impact of uremic toxins on vascular smooth muscle cell function. Toxins 10, 218 (2018).","journal-title":"Toxins"},{"key":"1006_CR121","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41581-023-00736-7","volume":"19","author":"P Evenepoel","year":"2023","unstructured":"Evenepoel, P., Stenvinkel, P., Shanahan, C. & Pacifici, R. Inflammation and gut dysbiosis as drivers of CKD-MBD. Nat. Rev. Nephrol. 19, 646\u2013657 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR122","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1681\/ASN.2017080929","volume":"29","author":"VB Kolachalama","year":"2018","unstructured":"Kolachalama, V. B. et al. Uremic solute-aryl hydrocarbon receptor-tissue factor axis associates with thrombosis after vascular injury in humans. J. Am. Soc. Nephrol. 29, 1063\u20131072 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR123","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142260","volume":"132","author":"NV Arinze","year":"2022","unstructured":"Arinze, N. V. et al. Tryptophan metabolites suppress the Wnt pathway and promote adverse limb events in chronic kidney disease. J. Clin. Invest. 132, e142260 (2022).","journal-title":"J. Clin. Invest."},{"key":"1006_CR124","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.kint.2015.11.020","volume":"89","author":"SC Hung","year":"2016","unstructured":"Hung, S. C. et al. Indoxyl sulfate suppresses endothelial progenitor cell-mediated neovascularization. Kidney Int. 89, 574\u2013585 (2016).","journal-title":"Kidney Int."},{"key":"1006_CR125","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.3390\/jcm13237149","volume":"13","author":"R Chermiti","year":"2024","unstructured":"Chermiti, R., Burtey, S. & Dou, L. Role of uremic toxins in vascular inflammation associated with chronic kidney disease. J. Clin. Med. 13, 7149 (2024).","journal-title":"J. Clin. Med."},{"key":"1006_CR126","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/toxins11040209","volume":"11","author":"T Santana Machado","year":"2019","unstructured":"Santana Machado, T., Cerini, C. & Burtey, S. Emerging roles of aryl hydrocarbon receptors in the altered clearance of drugs during chronic kidney disease. Toxins 11, 209 (2019).","journal-title":"Toxins"},{"key":"1006_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114220","volume":"182","author":"KW Bock","year":"2020","unstructured":"Bock, K. W. Aryl hydrocarbon receptor (AHR)-mediated inflammation and resolution: non-genomic and genomic signaling. Biochem. Pharmacol. 182, 114220 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"1006_CR128","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41581-021-00408-4","volume":"17","author":"JD Ravid","year":"2021","unstructured":"Ravid, J. D., Kamel, M. H. & Chitalia, V. C. Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease. Nat. Rev. Nephrol. 17, 402\u2013416 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR129","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00204-018-2328-3","volume":"93","author":"T Addi","year":"2019","unstructured":"Addi, T. et al. Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor\/nuclear factor-kappa B signaling pathway in human endothelial cells. Arch. Toxicol. 93, 121\u2013136 (2019).","journal-title":"Arch. Toxicol."},{"key":"1006_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002000","volume":"21","author":"AR Merchak","year":"2023","unstructured":"Merchak, A. R. et al. The activity of the aryl hydrocarbon receptor in T cells tunes the gut microenvironment to sustain autoimmunity and neuroinflammation. PLoS Biol. 21, e3002000 (2023).","journal-title":"PLoS Biol."},{"key":"1006_CR131","doi-asserted-by":"publisher","first-page":"eaba0624","DOI":"10.1126\/scitranslmed.aba0624","volume":"12","author":"B Lamas","year":"2020","unstructured":"Lamas, B. et al. Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Sci. Transl. Med. 12, eaba0624 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1006_CR132","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41586-023-06508-4","volume":"621","author":"BG Wiggins","year":"2023","unstructured":"Wiggins, B. G. et al. Endothelial sensing of AHR ligands regulates intestinal homeostasis. Nature 621, 821\u2013829 (2023).","journal-title":"Nature"},{"key":"1006_CR133","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186423","volume":"135","author":"B Schnabl","year":"2025","unstructured":"Schnabl, B., Damman, C. J. & Carr, R. M. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations. J. Clin. Investig. 135, e186423 (2025).","journal-title":"J. Clin. Investig."},{"key":"1006_CR134","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2017.11.010","volume":"93","author":"L Dou","year":"2018","unstructured":"Dou, L. et al. Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease. Kidney Int. 93, 986\u2013999 (2018).","journal-title":"Kidney Int."},{"key":"1006_CR135","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.kint.2016.06.041","volume":"90","author":"P Evenepoel","year":"2016","unstructured":"Evenepoel, P., Bover, J. & Ure\u00f1a Torres, P. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int. 90, 1184\u20131190 (2016).","journal-title":"Kidney Int."},{"key":"1006_CR136","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41564-024-01737-3","volume":"9","author":"AK Sinha","year":"2024","unstructured":"Sinha, A. K. et al. Dietary fibre directs microbial tryptophan metabolism via metabolic interactions in the gut microbiota. Nat. Microbiol. 9, 1964\u20131978 (2024).","journal-title":"Nat. Microbiol."},{"key":"1006_CR137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167671","volume":"134","author":"BJ Seymour","year":"2023","unstructured":"Seymour, B. J. et al. Microbiota-dependent indole production stimulates the development of collagen-induced arthritis in mice. J. Clin. Invest. 134, e167671 (2023).","journal-title":"J. Clin. Invest."},{"key":"1006_CR138","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1525-1594.1993.tb00628.x","volume":"17","author":"ND Vaziri","year":"1993","unstructured":"Vaziri, N. D., Oveisi, F., Wierszbiezki, M., Shaw, V. & Sporty, L. D. Serum melatonin and 6-sulfatoxymelatonin in end-stage renal disease: effect of hemodialysis. Artif. Organs 17, 764\u2013769 (1993).","journal-title":"Artif. Organs"},{"key":"1006_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10476-6","volume":"12","author":"R Takahashi","year":"2022","unstructured":"Takahashi, R. et al. The significance of NAD\u2009+\u2009metabolites and nicotinamide N-methyltransferase in chronic kidney disease. Sci. Rep. 12, 6398 (2022).","journal-title":"Sci. Rep."},{"key":"1006_CR140","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1681\/ASN.2020091310","volume":"32","author":"JA Walker","year":"2021","unstructured":"Walker, J. A. et al. Indoleamine 2,3-dioxygenase-1, a novel therapeutic target for post-vascular injury thrombosis in CKD. J. Am. Soc. Nephrol. 32, 2834\u20132850 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR141","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.2215\/CJN.03150318","volume":"13","author":"RD Mair","year":"2018","unstructured":"Mair, R. D., Sirich, T. L., Plummer, N. S. & Meyer, T. W. Characteristics of colon-derived uremic solutes. Clin. J. Am. Soc. Nephrol. 13, 1398\u20131404 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1006_CR142","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01331-23","volume":"14","author":"I Nemet","year":"2023","unstructured":"Nemet, I. et al. Microbe-derived uremic solutes enhance thrombosis potential in the host. mBio 14, e0133123 (2023).","journal-title":"mBio"},{"key":"1006_CR143","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1093\/eurheartj\/ehad333","volume":"44","author":"I Nemet","year":"2023","unstructured":"Nemet, I. et al. Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality. Eur. Heart J. 44, 3085\u20133096 (2023).","journal-title":"Eur. Heart J."},{"key":"1006_CR144","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/CIRCRESAHA.116.305360","volume":"116","author":"WH Tang","year":"2015","unstructured":"Tang, W. H. et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 116, 448\u2013455 (2015).","journal-title":"Circ. Res."},{"key":"1006_CR145","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/cts.12481","volume":"10","author":"A Chapron","year":"2017","unstructured":"Chapron, A. et al. Does secretory clearance follow glomerular filtration rate in chronic kidney diseases? Reconsidering the intact nephron hypothesis. Clin. Transl. Sci. 10, 395\u2013403 (2017).","journal-title":"Clin. Transl. Sci."},{"key":"1006_CR146","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.kint.2016.09.052","volume":"91","author":"J Lowenstein","year":"2017","unstructured":"Lowenstein, J. & Grantham, J. J. Residual renal function: a paradigm shift. Kidney Int. 91, 561\u2013565 (2017).","journal-title":"Kidney Int."},{"key":"1006_CR147","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1093\/ndt\/gfm210","volume":"22","author":"G Cohen","year":"2007","unstructured":"Cohen, G. et al. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro \u2014 towards a standardized approach for research on uraemia. Nephrol. Dial. Transplant. 22, 3381\u20133390 (2007).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR148","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2014010042","volume":"26","author":"G Schulman","year":"2015","unstructured":"Schulman, G. et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J. Am. Soc. Nephrol. 26, 1732\u20131746 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.676345","volume":"12","author":"PY Su","year":"2021","unstructured":"Su, P. Y. et al. Efficacy of AST-120 for patients with chronic kidney disease: a network meta-analysis of randomized controlled trials. Front. Pharmacol. 12, 676345 (2021).","journal-title":"Front. Pharmacol."},{"key":"1006_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082506","volume":"8","author":"C Pietrement","year":"2013","unstructured":"Pietrement, C., Gorisse, L., Jaisson, S. & Gillery, P. Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD. PLoS ONE 8, e82506 (2013).","journal-title":"PLoS ONE"},{"key":"1006_CR151","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/ki.2015.166","volume":"88","author":"FH Verbrugge","year":"2015","unstructured":"Verbrugge, F. H., Tang, W. H. & Hazen, S. L. Protein carbamylation and cardiovascular disease. Kidney Int. 88, 474\u2013478 (2015).","journal-title":"Kidney Int."},{"key":"1006_CR152","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1046\/j.1523-1755.2000.07615.x","volume":"76","author":"T Miyata","year":"2000","unstructured":"Miyata, T., Kurokawa, K. & van Ypersele de Strihou, C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int. Suppl. 76, S120\u2013S125 (2000).","journal-title":"Kidney Int. Suppl."},{"key":"1006_CR153","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/toxins12090567","volume":"12","author":"CO Soulage","year":"2020","unstructured":"Soulage, C. O. et al. Two toxic lipid aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), accumulate in patients with chronic kidney disease. Toxins 12, 567 (2020).","journal-title":"Toxins"},{"key":"1006_CR154","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1681\/ASN.2004080635","volume":"16","author":"S Agalou","year":"2005","unstructured":"Agalou, S., Ahmed, N., Babaei-Jadidi, R., Dawnay, A. & Thornalley, P. J. Profound mishandling of protein glycation degradation products in uremia and dialysis. J. Am. Soc. Nephrol. 16, 1471\u20131485 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR155","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/sj.ki.5002513","volume":"72","author":"N Rabbani","year":"2007","unstructured":"Rabbani, N., Sebekova, K., Sebekova, K. Jr., Heidland, A. & Thornalley, P. J. Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney Int. 72, 1113\u20131121 (2007).","journal-title":"Kidney Int."},{"key":"1006_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1238706","volume":"14","author":"Z Liu","year":"2023","unstructured":"Liu, Z., Yang, J., Du, M. & Xin, W. Functioning and mechanisms of PTMs in renal diseases. Front. Pharmacol. 14, 1238706 (2023).","journal-title":"Front. Pharmacol."},{"key":"1006_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101066","volume":"86","author":"J Hermann","year":"2022","unstructured":"Hermann, J., Schurgers, L. & Jankowski, V. Identification and characterization of post-translational modifications: clinical implications. Mol. Aspects Med. 86, 101066 (2022).","journal-title":"Mol. Aspects Med."},{"key":"1006_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2022.101956","volume":"76","author":"D Bradley","year":"2022","unstructured":"Bradley, D. The evolution of post-translational modifications. Curr. Opin. Genet. Dev. 76, 101956 (2022).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"1006_CR159","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.1074\/jbc.M117.801076","volume":"293","author":"C Delporte","year":"2018","unstructured":"Delporte, C. et al. Myeloperoxidase-catalyzed oxidation of cyanide to cyanate: a potential carbamylation route involved in the formation of atherosclerotic plaques? J. Biol. Chem. 293, 6374\u20136386 (2018).","journal-title":"J. Biol. Chem."},{"key":"1006_CR160","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.kint.2021.10.018","volume":"101","author":"V Jankowski","year":"2022","unstructured":"Jankowski, V. et al. Carbamylated sortilin associates with cardiovascular calcification in patients with chronic kidney disease. Kidney Int. 101, 574\u2013584 (2022).","journal-title":"Kidney Int."},{"key":"1006_CR161","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehu111","volume":"35","author":"T Speer","year":"2014","unstructured":"Speer, T. et al. Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur. Heart J. 35, 3021\u20133032 (2014).","journal-title":"Eur. Heart J."},{"key":"1006_CR162","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ndt\/gfaa347","volume":"37","author":"S Kalim","year":"2021","unstructured":"Kalim, S. et al. Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study. Nephrol. Dial. Transplant. 37, 139\u2013147 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR163","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2337\/dc22-1399","volume":"46","author":"M Tang","year":"2023","unstructured":"Tang, M. et al. The impact of carbamylation and anemia on HbA1c\u2019s association with renal outcomes in patients with diabetes and chronic kidney disease. Diabetes Care 46, 130\u2013137 (2023).","journal-title":"Diabetes Care"},{"key":"1006_CR164","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/apha.12518","volume":"215","author":"M Rueth","year":"2015","unstructured":"Rueth, M. et al. Guanidinylations of albumin decreased binding capacity of hydrophobic metabolites. Acta Physiol. 215, 13\u201323 (2015).","journal-title":"Acta Physiol."},{"key":"1006_CR165","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1681\/ASN.2010040365","volume":"21","author":"EO Apostolov","year":"2010","unstructured":"Apostolov, E. O., Ray, D., Savenka, A. V., Shah, S. V. & Basnakian, A. G. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J. Am. Soc. Nephrol. 21, 1852\u20131857 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR166","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.kint.2025.02.010","volume":"107","author":"A Bonnin-Marquez","year":"2025","unstructured":"Bonnin-Marquez, A. et al. Guanidinylation compromises the anti-inflammatory and anti-oxidative properties of apolipoprotein A-I in chronic kidney disease progression. Kidney Int. 107, 916\u2013929 (2025).","journal-title":"Kidney Int."},{"key":"1006_CR167","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1681\/ASN.2021040503","volume":"32","author":"SJ Schunk","year":"2021","unstructured":"Schunk, S. J. et al. Guanidinylated apolipoprotein C3 (ApoC3) associates with kidney and vascular injury. J. Am. Soc. Nephrol. 32, 3146\u20133160 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR168","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","volume":"21","author":"S Zewinger","year":"2020","unstructured":"Zewinger, S. et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat. Immunol. 21, 30\u201341 (2020).","journal-title":"Nat. Immunol."},{"key":"1006_CR169","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1681\/ASN.2016030336","volume":"28","author":"K Schuett","year":"2017","unstructured":"Schuett, K. et al. Clot structure: a potent mortality risk factor in patients on hemodialysis. J. Am. Soc. Nephrol. 28, 1622\u20131630 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR170","first-page":"S658","volume":"9","author":"V Jankowski","year":"2024","unstructured":"Jankowski, V., Lellig, M. & Jankowski, J. WCN24-66 Post-translational guanidinylation of the HDL protein ApoA-1. Kidney Int. Rep. 9, S658 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1006_CR171","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/cvr\/cvs089","volume":"94","author":"M T\u00f6lle","year":"2012","unstructured":"T\u00f6lle, M. et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc. Res. 94, 154\u2013162 (2012).","journal-title":"Cardiovasc. Res."},{"key":"1006_CR172","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1089\/ars.2020.8184","volume":"35","author":"T Ebert","year":"2021","unstructured":"Ebert, T. et al. Inflammation and oxidative stress in chronic kidney disease and dialysis patients. Antioxid. Redox Signal. 35, 1426\u20131448 (2021).","journal-title":"Antioxid. Redox Signal."},{"key":"1006_CR173","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.3390\/ijms22094642","volume":"22","author":"CA Juan","year":"2021","unstructured":"Juan, C. A., P\u00e9rez de la Lastra, J. M., Plou, F. J. & P\u00e9rez-Lebe\u00f1a, E. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. Int. J. Mol. Sci. 22, 4642 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1006_CR174","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1681\/ASN.2019111205","volume":"31","author":"N Florens","year":"2020","unstructured":"Florens, N. et al. CKD increases carbonylation of HDL and is associated with impaired antiaggregant properties. J. Am. Soc. Nephrol. 31, 1462\u20131477 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR175","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/jcb.25017","volume":"116","author":"S Hoffman","year":"2015","unstructured":"Hoffman, S. et al. Thiol redox chemistry: role of protein cysteine oxidation and altered redox homeostasis in allergic inflammation and asthma. J. Cell. Biochem. 116, 884\u2013892 (2015).","journal-title":"J. Cell. Biochem."},{"key":"1006_CR176","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4330\/wjc.v8.i12.689","volume":"8","author":"E Amiya","year":"2016","unstructured":"Amiya, E. Interaction of hyperlipidemia and reactive oxygen species: Insights from the lipid-raft platform. World J. Cardiol. 8, 689\u2013694 (2016).","journal-title":"World J. Cardiol."},{"key":"1006_CR177","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.3390\/ijms23137329","volume":"23","author":"C Reyes","year":"2022","unstructured":"Reyes, C. et al. Loxin reduced the inflammatory response in the liver and the aortic fatty streak formation in mice fed with a high-fat diet. Int. J. Mol. Sci. 23, 7329 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1006_CR178","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.bbrc.2019.04.082","volume":"513","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. High glucose\/ox-LDL induced hepatic sinusoidal capillarization via \u03b1v\u03b25\/FAK\/ERK signaling pathway. Biochem. Biophys. Res. Commun. 513, 1055\u20131062 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1006_CR179","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/emmm.201200224","volume":"4","author":"C Besler","year":"2012","unstructured":"Besler, C., L\u00fcscher, T. F. & Landmesser, U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol. Med. 4, 251\u2013268 (2012).","journal-title":"EMBO Mol. Med."},{"key":"1006_CR180","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1258\/0004563001899186","volume":"37","author":"T Nakajima","year":"2000","unstructured":"Nakajima, T. et al. Localization of oxidized HDL in atheromatous plaques and oxidized HDL binding sites on human aortic endothelial cells. Ann. Clin. Biochem. 37, 179\u2013186 (2000).","journal-title":"Ann. Clin. Biochem."},{"key":"1006_CR181","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.febslet.2007.02.043","volume":"581","author":"RF Thorne","year":"2007","unstructured":"Thorne, R. F., Mhaidat, N. M., Ralston, K. J. & Burns, G. F. CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. FEBS Lett. 581, 1227\u20131232 (2007).","journal-title":"FEBS Lett."},{"key":"1006_CR182","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/toxins12040245","volume":"12","author":"G Glorieux","year":"2020","unstructured":"Glorieux, G., Gryp, T. & Perna, A. Gut-derived metabolites and their role in immune dysfunction in chronic kidney disease. Toxins 12, 245 (2020).","journal-title":"Toxins"},{"key":"1006_CR183","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"1006_CR184","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","volume":"149","author":"AM Billing","year":"2024","unstructured":"Billing, A. M. et al. Metabolic communication by SGLT2 inhibition. Circulation 149, 860\u2013884 (2024).","journal-title":"Circulation"},{"key":"1006_CR185","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2300314","volume":"46","author":"L He","year":"2024","unstructured":"He, L. et al. Canagliflozin attenuates kidney injury, gut-derived toxins, and gut microbiota imbalance in high-salt diet-fed Dahl salt-sensitive rats. Ren. Fail. 46, 2300314 (2024).","journal-title":"Ren. Fail."},{"key":"1006_CR186","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10157-022-02312-y","volume":"27","author":"A Matsui","year":"2023","unstructured":"Matsui, A. et al. Canagliflozin protects the cardiovascular system through effects on the gut environment in non-diabetic nephrectomized rats. Clin. Exp. Nephrol. 27, 295\u2013308 (2023).","journal-title":"Clin. Exp. Nephrol."},{"key":"1006_CR187","doi-asserted-by":"publisher","first-page":"F824","DOI":"10.1152\/ajprenal.00314.2017","volume":"315","author":"E Mishima","year":"2018","unstructured":"Mishima, E. et al. Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Am. J. Physiol. Renal Physiol. 315, F824\u2013F833 (2018).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1006_CR188","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/psp4.12498","volume":"9","author":"V Sokolov","year":"2020","unstructured":"Sokolov, V. et al. Differentiating the sodium-glucose cotransporter 1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling. CPT Pharmacometrics Syst. Pharmacol. 9, 222\u2013229 (2020).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"1006_CR189","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034026","volume":"7","author":"CY Sun","year":"2012","unstructured":"Sun, C. Y., Chang, S. C. & Wu, M. S. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS ONE 7, e34026 (2012).","journal-title":"PLoS ONE"},{"key":"1006_CR190","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10157-020-01892-x","volume":"24","author":"A Iguchi","year":"2020","unstructured":"Iguchi, A. et al. Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis. Clin. Exp. Nephrol. 24, 725\u2013733 (2020).","journal-title":"Clin. Exp. Nephrol."},{"key":"1006_CR191","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1124\/jpet.118.251389","volume":"367","author":"WL Lau","year":"2018","unstructured":"Lau, W. L. et al. The phosphate binder ferric citrate alters the gut microbiome in rats with chronic kidney disease. J. Pharmacol. Exp. Ther. 367, 452\u2013460 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1006_CR192","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/toxins13020091","volume":"13","author":"SM Laville","year":"2021","unstructured":"Laville, S. M. et al. Intestinal chelators, sorbants, and gut-derived uremic toxins. Toxins 13, 91 (2021).","journal-title":"Toxins"},{"key":"1006_CR193","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1681\/ASN.2010121220","volume":"22","author":"PA Aronov","year":"2011","unstructured":"Aronov, P. A. et al. Colonic contribution to uremic solutes. J. Am. Soc. Nephrol. 22, 1769\u20131776 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR194","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.kint.2024.01.040","volume":"105","author":"J Lee","year":"2024","unstructured":"Lee, J. et al. Antibiotic-induced intestinal microbiota depletion can attenuate the acute kidney injury to chronic kidney disease transition via NADPH oxidase 2 and trimethylamine-N-oxide inhibition. Kidney Int. 105, 1239\u20131253 (2024).","journal-title":"Kidney Int."},{"key":"1006_CR195","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.ekir.2021.05.014","volume":"6","author":"L Nazzal","year":"2021","unstructured":"Nazzal, L. et al. Effect of vancomycin on the gut microbiome and plasma concentrations of gut-derived uremic solutes. Kidney Int. Rep. 6, 2122\u20132133 (2021).","journal-title":"Kidney Int. Rep."},{"key":"1006_CR196","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/MNH.0000000000000753","volume":"31","author":"K Sumida","year":"2022","unstructured":"Sumida, K., Lau, W. L., Kalantar-Zadeh, K. & Kovesdy, C. P. Novel intestinal dialysis interventions and microbiome modulation to control uremia. Curr. Opin. Nephrol. Hypertens. 31, 82\u201391 (2022).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"1006_CR197","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.93","volume":"1","author":"HM Roager","year":"2016","unstructured":"Roager, H. M. et al. Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nat. Microbiol. 1, 16093 (2016).","journal-title":"Nat. Microbiol."},{"key":"1006_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83855-w","volume":"14","author":"K Kim","year":"2024","unstructured":"Kim, K., Cho, W. H., Hwang, S. D., Lee, S. W. & Song, J. H. Association between constipation and incident chronic kidney disease in the UK Biobank study. Sci. Rep. 14, 32106 (2024).","journal-title":"Sci. Rep."},{"key":"1006_CR199","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1681\/ASN.2016060656","volume":"28","author":"K Sumida","year":"2017","unstructured":"Sumida, K. et al. Constipation and incident CKD. J. Am. Soc. Nephrol. 28, 1248\u20131258 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR200","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/ndt\/gfaa205","volume":"36","author":"K Sumida","year":"2021","unstructured":"Sumida, K. et al. Laxative use in patients with advanced chronic kidney disease transitioning to dialysis. Nephrol. Dial. Transplant. 36, 2018\u20132026 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR201","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/ndt\/gfz126","volume":"35","author":"F Nanto-Hara","year":"2020","unstructured":"Nanto-Hara, F. et al. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. Nephrol. Dial. Transplant. 35, 250\u2013264 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR202","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1007\/s10157-019-01727-4","volume":"23","author":"M Sueyoshi","year":"2019","unstructured":"Sueyoshi, M. et al. Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats. Clin. Exp. Nephrol. 23, 908\u2013919 (2019).","journal-title":"Clin. Exp. Nephrol."},{"key":"1006_CR203","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/ndt\/gfac277","volume":"37","author":"N Benech","year":"2022","unstructured":"Benech, N. & Koppe, L. Is there a place for faecal microbiota transplantation in chronic kidney disease? Nephrol. Dial. Transplant. 37, 2303\u20132306 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR204","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0357-9","volume":"17","author":"G Schulman","year":"2016","unstructured":"Schulman, G. et al. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. BMC Nephrol. 17, 141 (2016).","journal-title":"BMC Nephrol."},{"key":"1006_CR205","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.colsurfb.2012.04.020","volume":"100","author":"H Abe","year":"2012","unstructured":"Abe, H. & Otsuka, M. Comparison of physico-chemical characteristics among three pharmaceutical spherical carbon adsorbents. Colloids Surf. B Biointerfaces 100, 90\u201394 (2012).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"1006_CR206","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1021\/jacs.8b12525","volume":"141","author":"S Kato","year":"2019","unstructured":"Kato, S. et al. Zirconium-based metal-organic frameworks for the removal of protein-bound uremic toxin from human serum albumin. J. Am. Chem. Soc. 141, 2568\u20132576 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"1006_CR207","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38427-3","volume":"14","author":"J Wei","year":"2023","unstructured":"Wei, J. et al. Efficient selective removal of uremic toxin precursor by olefin-linked covalent organic frameworks for nephropathy treatment. Nat. Commun. 14, 2805 (2023).","journal-title":"Nat. Commun."},{"key":"1006_CR208","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.cell.2015.11.055","volume":"163","author":"Z Wang","year":"2015","unstructured":"Wang, Z. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585\u20131595 (2015).","journal-title":"Cell"},{"key":"1006_CR209","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.chembiol.2023.07.015","volume":"30","author":"AL Graboski","year":"2023","unstructured":"Graboski, A. L. et al. Mechanism-based inhibition of gut microbial tryptophanases reduces serum indoxyl sulfate. Cell Chem. Biol. 30, 1402\u20131413.e7 (2023).","journal-title":"Cell Chem. Biol."},{"key":"1006_CR210","doi-asserted-by":"publisher","first-page":"eaam8475","DOI":"10.1126\/scitranslmed.aam8475","volume":"9","author":"M Shashar","year":"2017","unstructured":"Shashar, M. et al. Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk. Sci. Transl. Med. 9, eaam8475 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1006_CR211","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41575-021-00430-8","volume":"18","author":"B Stockinger","year":"2021","unstructured":"Stockinger, B., Shah, K. & Wincent, E. AHR in the intestinal microenvironment: safeguarding barrier function. Nat. Rev. Gastroenterol. Hepatol. 18, 559\u2013570 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1006_CR212","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nature12480","volume":"500","author":"A Cotillard","year":"2013","unstructured":"Cotillard, A. et al. Dietary intervention impact on gut microbial gene richness. Nature 500, 585\u2013588 (2013).","journal-title":"Nature"},{"key":"1006_CR213","doi-asserted-by":"publisher","first-page":"14691","DOI":"10.1073\/pnas.1005963107","volume":"107","author":"C De Filippo","year":"2010","unstructured":"De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl Acad. Sci. USA 107, 14691\u201314696 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1006_CR214","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.1124234","volume":"312","author":"SR Gill","year":"2006","unstructured":"Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome. Science 312, 1355\u20131359 (2006).","journal-title":"Science"},{"key":"1006_CR215","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","volume":"76","author":"TA Ikizler","year":"2020","unstructured":"Ikizler, T. A. et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am. J. Kidney Dis. 76, S1\u2013s107 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"1006_CR216","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1056\/NEJMra1700312","volume":"377","author":"K Kalantar-Zadeh","year":"2017","unstructured":"Kalantar-Zadeh, K. & Fouque, D. Nutritional management of chronic kidney disease. N. Engl. J. Med. 377, 1765\u20131776 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR217","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.kint.2022.06.025","volume":"102","author":"L Koppe","year":"2022","unstructured":"Koppe, L. & Soulage, C. O. The impact of dietary nutrient intake on gut microbiota in the progression and complications of chronic kidney disease. Kidney Int. 102, 728\u2013739 (2022).","journal-title":"Kidney Int."},{"key":"1006_CR218","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41581-020-0297-2","volume":"16","author":"JJ Carrero","year":"2020","unstructured":"Carrero, J. J. et al. Plant-based diets to manage the risks and complications of chronic kidney disease. Nat. Rev. Nephrol. 16, 525\u2013542 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR219","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/toxins10040155","volume":"10","author":"L Koppe","year":"2018","unstructured":"Koppe, L., Fouque, D. & Soulage, C. O. The role of gut microbiota and diet on uremic retention solutes production in the context of chronic kidney disease. Toxins 10, 155 (2018).","journal-title":"Toxins"},{"key":"1006_CR220","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.3390\/nu12123892","volume":"12","author":"P Letourneau","year":"2020","unstructured":"Letourneau, P., Bataille, S., Chauveau, P., Fouque, D. & Koppe, L. Source and composition in amino acid of dietary proteins in the primary prevention and treatment of CKD. Nutrients 12, 3892 (2020).","journal-title":"Nutrients"},{"key":"1006_CR221","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3390\/nu11092071","volume":"11","author":"L Koppe","year":"2019","unstructured":"Koppe, L., Cassani de Oliveira, M. & Fouque, D. Ketoacid analogues supplementation in chronic kidney disease and future perspectives. Nutrients 11, 2071 (2019).","journal-title":"Nutrients"},{"key":"1006_CR222","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2215\/CJN.0000000682","volume":"20","author":"J Stanford","year":"2025","unstructured":"Stanford, J. et al. High-diversity plant-based diet and gut microbiome, plasma metabolome, and symptoms in adults with CKD. Clin. J. Am. Soc. Nephrol. 20, 619\u2013631 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1006_CR223","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.jrn.2020.07.008","volume":"31","author":"J Stanford","year":"2021","unstructured":"Stanford, J. et al. Associations among plant-based diet quality, uremic toxins, and gut microbiota profile in adults undergoing hemodialysis therapy. J. Ren. Nutr. 31, 177\u2013188 (2021).","journal-title":"J. Ren. Nutr."},{"key":"1006_CR224","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.ajkd.2020.04.019","volume":"77","author":"EA Hu","year":"2021","unstructured":"Hu, E. A. et al. Adherence to healthy dietary patterns and risk of CKD progression and all-cause mortality: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. Am. J. Kidney Dis. 77, 235\u2013244 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"1006_CR225","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2215\/CJN.06190616","volume":"12","author":"JT Kelly","year":"2017","unstructured":"Kelly, J. T. et al. Healthy dietary patterns and risk of mortality and ESRD in CKD: a meta-analysis of cohort studies. Clin. J. Am. Soc. Nephrol. 12, 272\u2013279 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1006_CR226","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.clnu.2021.12.041","volume":"41","author":"A Podadera-Herreros","year":"2022","unstructured":"Podadera-Herreros, A. et al. Long-term consumption of a Mediterranean diet or a low-fat diet on kidney function in coronary heart disease patients: the CORDIOPREV randomized controlled trial. Clin. Nutr. 41, 552\u2013559 (2022).","journal-title":"Clin. Nutr."},{"key":"1006_CR227","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/ndt\/gfv353","volume":"31","author":"A Yoshifuji","year":"2016","unstructured":"Yoshifuji, A. et al. Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol. Dial. Transplant. 31, 401\u2013412 (2016).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1006_CR228","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98718-x","volume":"11","author":"C Barba","year":"2021","unstructured":"Barba, C. et al. A low aromatic amino-acid diet improves renal function and prevent kidney fibrosis in mice with chronic kidney disease. Sci. Rep. 11, 19184 (2021).","journal-title":"Sci. Rep."},{"key":"1006_CR229","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1126\/science.abb3763","volume":"369","author":"L Lobel","year":"2020","unstructured":"Lobel, L., Cao, Y. G., Fenn, K., Glickman, J. N. & Garrett, W. S. Diet posttranslationally modifies the mouse gut microbial proteome to modulate renal function. Science 369, 1518\u20131524 (2020).","journal-title":"Science"},{"key":"1006_CR230","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1136\/gutjnl-2019-319766","volume":"69","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut 69, 2131\u20132142 (2020).","journal-title":"Gut"},{"key":"1006_CR231","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41581-020-00345-8","volume":"17","author":"D Mafra","year":"2021","unstructured":"Mafra, D. et al. Food as medicine: targeting the uraemic phenotype in chronic kidney disease. Nat. Rev. Nephrol. 17, 153\u2013171 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR232","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41575-024-00893-5","volume":"21","author":"K Whelan","year":"2024","unstructured":"Whelan, K., Bancil, A. S., Lindsay, J. O. & Chassaing, B. Ultra-processed foods and food additives in gut health and disease. Nat. Rev. Gastroenterol. Hepatol. 21, 406\u2013427 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1006_CR233","doi-asserted-by":"publisher","first-page":"173","DOI":"10.23736\/S0031-0808.16.03282-1","volume":"59","author":"L Koppe","year":"2017","unstructured":"Koppe, L. & Fouque, D. Microbiota and prebiotics modulation of uremic toxin generation. Panminerva Med. 59, 173\u2013187 (2017).","journal-title":"Panminerva Med."},{"key":"1006_CR234","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/ki.2015.255","volume":"88","author":"L Koppe","year":"2015","unstructured":"Koppe, L., Mafra, D. & Fouque, D. Probiotics and chronic kidney disease. Kidney Int. 88, 958\u2013966 (2015).","journal-title":"Kidney Int."},{"key":"1006_CR235","first-page":"CD013631","volume":"10","author":"TE Cooper","year":"2023","unstructured":"Cooper, T. E. et al. Synbiotics, prebiotics and probiotics for people with chronic kidney disease. Cochrane Database Syst. Rev. 10, CD013631 (2023).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1006_CR236","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1434613","volume":"11","author":"C Liu","year":"2024","unstructured":"Liu, C., Yang, L., Wei, W. & Fu, P. Efficacy of probiotics\/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Front. Nutr. 11, 1434613 (2024).","journal-title":"Front. Nutr."},{"key":"1006_CR237","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.jrn.2021.08.005","volume":"32","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Biotic supplements in patients with chronic kidney disease: meta-analysis of randomized controlled trials. J. Ren. Nutr. 32, 10\u201321 (2022).","journal-title":"J. Ren. Nutr."},{"key":"1006_CR238","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s12602-024-10427-9","volume":"17","author":"FPB Ribeiro","year":"2025","unstructured":"Ribeiro, F. P. B., de Luna Freire, M. O., de Oliveira Coutinho, D., de Santana Cirilo, M. A. & de Brito Alves, J. L. Gut dysbiosis and probiotic therapy in chronic kidney disease: a comprehensive review. Probiotics Antimicrob. Proteins 17, 1797\u20131819 (2025).","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"1006_CR239","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3390\/jcm12051948","volume":"12","author":"L Voroneanu","year":"2023","unstructured":"Voroneanu, L. et al. Gut microbiota in chronic kidney disease: from composition to modulation towards better outcomes-a systematic review. J. Clin. Med. 12, 1948 (2023).","journal-title":"J. Clin. Med."},{"key":"1006_CR240","volume":"20","author":"S More","year":"2022","unstructured":"More, S. et al. Evaluation of existing guidelines for their adequacy for the food and feed risk assessment of microorganisms obtained through synthetic biology. EFSA 20, e07479 (2022).","journal-title":"EFSA"},{"key":"1006_CR241","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.940228","volume":"13","author":"J Cao","year":"2022","unstructured":"Cao, J. et al. Lactobacillus paracasei X11 ameliorates hyperuricemia and modulates gut microbiota in mice. Front. Immunol. 13, 940228 (2022).","journal-title":"Front. Immunol."},{"key":"1006_CR242","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1161\/CIRCRESAHA.122.320184","volume":"131","author":"HB Li","year":"2022","unstructured":"Li, H. B. et al. Faecalibacterium prausnitzii Attenuates CKD via Butyrate-Renal GPR43 Axis. Circulation Res. 131, e120\u2013e134 (2022).","journal-title":"Circulation Res."},{"key":"1006_CR243","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.cmet.2021.08.015","volume":"33","author":"H Zhu","year":"2021","unstructured":"Zhu, H. et al. The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease. Cell Metab. 33, 2091\u20132093 (2021).","journal-title":"Cell Metab."},{"key":"1006_CR244","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/toxins13040246","volume":"13","author":"S Magnani","year":"2021","unstructured":"Magnani, S. & Atti, M. Uremic toxins and blood purification: a review of current evidence and future perspectives. Toxins 13, 246 (2021).","journal-title":"Toxins"},{"key":"1006_CR245","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/sdi.13097","volume":"35","author":"JC de Vries","year":"2022","unstructured":"de Vries, J. C. et al. Evidence on continuous flow peritoneal dialysis: a review. Semin. Dial. 35, 481\u2013497 (2022).","journal-title":"Semin. Dial."},{"key":"1006_CR246","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3390\/jcm13051428","volume":"13","author":"D S\u00e1nchez-Ospina","year":"2024","unstructured":"S\u00e1nchez-Ospina, D. et al. Displacing the burden: a review of protein-bound uremic toxin clearance strategies in chronic kidney disease. J. Clin. Med. 13, 1428 (2024).","journal-title":"J. Clin. Med."},{"key":"1006_CR247","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1056\/NEJMoa2304820","volume":"389","author":"PJ Blankestijn","year":"2023","unstructured":"Blankestijn, P. J. et al. Effect of hemodiafiltration or hemodialysis on mortality in kidney failure. N. Engl. J. Med. 389, 700\u2013709 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1006_CR248","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1681\/ASN.2011121140","volume":"23","author":"MP Grooteman","year":"2012","unstructured":"Grooteman, M. P. et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J. Am. Soc. Nephrol. 23, 1087\u20131096 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1006_CR249","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/toxins12040234","volume":"12","author":"MK van Gelder","year":"2020","unstructured":"van Gelder, M. K. et al. Protein-bound uremic toxins in hemodialysis patients relate to residual kidney function, are not influenced by convective transport, and do not relate to outcome. Toxins 12, 234 (2020).","journal-title":"Toxins"},{"key":"1006_CR250","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40620-023-01771-0","volume":"37","author":"M Fiorentino","year":"2024","unstructured":"Fiorentino, M., La Fergola, F. & De Rosa, S. Medium cut-off dialyzer for middle molecular uremic toxins in AKI and chronic dialysis. J. Nephrol. 37, 23\u201337 (2024).","journal-title":"J. Nephrol."},{"key":"1006_CR251","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1093\/ckj\/sfac167","volume":"15","author":"F Maduell","year":"2022","unstructured":"Maduell, F. et al. Comparison of four medium cut-off dialyzers. Clin. Kidney J. 15, 2292\u20132299 (2022).","journal-title":"Clin. Kidney J."},{"key":"1006_CR252","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.ki.5002750","volume":"73","author":"S Eloot","year":"2008","unstructured":"Eloot, S. et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int. 73, 765\u2013770 (2008).","journal-title":"Kidney Int."},{"key":"1006_CR253","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.3390\/ijerph16234864","volume":"16","author":"M Furue","year":"2019","unstructured":"Furue, M. & Tsuji, G. Chloracne and hyperpigmentation caused by exposure to hazardous aryl hydrocarbon receptor ligands. Int. J. Environ. Res. Public. Health 16, 4864 (2019).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"1006_CR254","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","volume":"403","author":"GBD 2021 Forecasting Collaborators","year":"2024","unstructured":"GBD 2021 Forecasting Collaborators Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the global burden of disease study 2021. Lancet 403, 2204\u20132256 (2024).","journal-title":"Lancet"},{"key":"1006_CR255","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41581-023-00726-9","volume":"19","author":"DL Ramada","year":"2023","unstructured":"Ramada, D. L. et al. Portable, wearable and implantable artificial kidney systems: needs, opportunities and challenges. Nat. Rev. Nephrol. 19, 481\u2013490 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"1006_CR256","doi-asserted-by":"publisher","DOI":"10.1007\/s10544-020-00539-8","volume":"23","author":"A Ghosh","year":"2021","unstructured":"Ghosh, A. et al. Effective clearance of uremic toxins using functionalised silicon Nanoporous membranes. Biomed. Microdevices 23, 4 (2021).","journal-title":"Biomed. Microdevices"},{"key":"1006_CR257","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1515\/bmt-2015-0149","volume":"62","author":"Q Zhang","year":"2017","unstructured":"Zhang, Q., Lu, X., Yang, S., Zhang, Q. & Zhao, L. Preparation of anticoagulant polyvinylidene fluoride hollow fiber hemodialysis membranes. Biomed. Tech. 62, 57\u201365 (2017).","journal-title":"Biomed. Tech."},{"key":"1006_CR258","doi-asserted-by":"publisher","first-page":"118187","DOI":"10.1016\/j.memsci.2020.118187","volume":"609","author":"D Kim","year":"2020","unstructured":"Kim, D. & Stamatialis, D. High flux mixed matrix membrane with low albumin leakage for blood plasma detoxification. J. Membr. Sci. 609, 118187 (2020).","journal-title":"J. Membr. Sci."},{"key":"1006_CR259","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/toxins13090622","volume":"13","author":"V Maheshwari","year":"2021","unstructured":"Maheshwari, V., Tao, X., Thijssen, S. & Kotanko, P. Removal of protein-bound uremic toxins using binding competitors in hemodialysis: a narrative review. Toxins 13, 622 (2021).","journal-title":"Toxins"},{"key":"1006_CR260","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3747\/pdi.2018.00229","volume":"39","author":"Y Shi","year":"2019","unstructured":"Shi, Y. et al. Removal of protein-bound uremic toxins by liposome-supported peritoneal dialysis. Perit. Dial. Int. 39, 509\u2013518 (2019).","journal-title":"Perit. Dial. Int."},{"key":"1006_CR261","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.kint.2025.06.004","volume":"108","author":"LA Raillon","year":"2025","unstructured":"Raillon, L. A. et al. Medium chain fatty acids are potent binding competitors to improve protein-bound uremic toxin clearance during hemodialysis. Kidney Int. 108, 411\u2013426 (2025).","journal-title":"Kidney Int."},{"key":"1006_CR262","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.chom.2016.10.021","volume":"20","author":"AS Devlin","year":"2016","unstructured":"Devlin, A. S. et al. Modulation of a circulating uremic solute via rational genetic manipulation of the gut microbiota. Cell Host Microbe 20, 709\u2013715 (2016).","journal-title":"Cell Host Microbe"},{"key":"1006_CR263","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1021\/acssynbio.3c00686","volume":"13","author":"D Lubkowicz","year":"2024","unstructured":"Lubkowicz, D., Hava, D. L., Lewis, K. & Isabella, V. M. Rational engineering of Escherichia coli Nissle 1917 as live biotherapeutic to degrade uremic toxin precursors. ACS Synth. Biol. 13, 1077\u20131084 (2024).","journal-title":"ACS Synth. Biol."},{"key":"1006_CR264","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/biomedicines12020453","volume":"12","author":"F De Chiara","year":"2024","unstructured":"De Chiara, F., Ferret-Mi\u00f1ana, A., Fern\u00e1ndez-Costa, J. M. & Ram\u00f3n-Azc\u00f3n, J. The tissue engineering revolution: from bench research to clinical reality. Biomedicines 12, 453 (2024).","journal-title":"Biomedicines"},{"key":"1006_CR265","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40472-023-00397-2","volume":"10","author":"BS Freedman","year":"2023","unstructured":"Freedman, B. S. & Dekel, B. Engraftment of kidney organoids in vivo. Curr. Transplant. Rep. 10, 29\u201339 (2023).","journal-title":"Curr. Transplant. Rep."},{"key":"1006_CR266","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/psp4.13110","volume":"13","author":"N Milani","year":"2024","unstructured":"Milani, N., Parrott, N., Galetin, A., Fowler, S. & Gertz, M. In silico modeling and simulation of organ-on-a-chip systems to support data analysis and a priori experimental design. CPT Pharmacometrics Syst. Pharmacol. 13, 524\u2013543 (2024).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"1006_CR267","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202400108","volume":"11\u201312","author":"MB Lopes","year":"2025","unstructured":"Lopes, M. B. et al. The omics-driven machine learning path to cost-effective precision medicine in chronic kidney disease. Proteomics 11\u201312, e202400108 (2025).","journal-title":"Proteomics"},{"key":"1006_CR268","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179733","volume":"12","author":"OL Aiyegbusi","year":"2017","unstructured":"Aiyegbusi, O. L. et al. Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: a systematic review. PLoS ONE 12, e0179733 (2017).","journal-title":"PLoS ONE"},{"key":"1006_CR269","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.kint.2018.08.018","volume":"94","author":"A Tong","year":"2018","unstructured":"Tong, A. et al. Implementing core outcomes in kidney disease: report of the standardized outcomes in nephrology (SONG) implementation workshop. Kidney Int. 94, 1053\u20131068 (2018).","journal-title":"Kidney Int."},{"key":"1006_CR270","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3390\/biom11081144","volume":"11","author":"AK Aranda-Rivera","year":"2021","unstructured":"Aranda-Rivera, A. K., Cruz-Gregorio, A., Aparicio-Trejo, O. E. & Pedraza-Chaverri, J. Mitochondrial redox signaling and oxidative stress in kidney diseases. Biomolecules 11, 1144 (2021).","journal-title":"Biomolecules"},{"key":"1006_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101901","volume":"42","author":"R Kehm","year":"2021","unstructured":"Kehm, R., Baldensperger, T., Raupbach, J. & H\u00f6hn, A. Protein oxidation \u2014 formation mechanisms, detection and relevance as biomarkers in human diseases. Redox Biol. 42, 101901 (2021).","journal-title":"Redox Biol."},{"key":"1006_CR272","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/antiox8020050","volume":"8","author":"YJ Suzuki","year":"2019","unstructured":"Suzuki, Y. J. Oxidant-mediated protein amino acid conversion. Antioxidants 8, 50 (2019).","journal-title":"Antioxidants"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01006-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01006-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01006-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:02:35Z","timestamp":1765890155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01006-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":272,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-01006-4","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"28 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The EUTox Work Group (of which all authors are members)\u00a0receives unrestricted grants from Fresenius Medical Care, Baxter Healthcare and B. Braun Avitum AG. S.B. received honoraria for conferences from Astra-Zeneca, Amgen, Lilly and Vifor CLS. L.K. has received grants from Fresenius Kabi, Nestl\u00e9, Lallemand, AstraZeneca, and consultancy or speaker fees or travel support from AstraZeneca, Lilly, Baxter, Bayer and Fresenius Kabi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}